Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. Result of Annual General Meeting 2022

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Annual General Meeting 2022

7 Jun 2022 16:45

Arix Bioscience PLC (ARIX) Result of Annual General Meeting 2022 07-Jun-2022 / 16:44 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

 

Arix Bioscience plc

 

Result of Annual General Meeting 2022

 

LONDON, 7 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website.

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2021

63,669,622

99.99%

5,609

0.01%

63,675,231

49.29%

10,853

2

To approve the Directors' Remuneration Policy

63,589,770

99.90%

65,188

0.10%

63,654,958

49.28%

31,126

3

To approve the Directors' Remuneration Report

60,232,861

94.62%

3,422,747

5.38%

63,655,608

49.28%

30,476

4

To re-elect Peregrine Moncreiffe as a Director

60,068,424

94.35%

3,599,164

5.65%

63,667,588

49.29%

18,496

5

To re-elect Maureen O'Connell as a Director

59,600,160

93.61%

4,068,028

6.39%

63,668,188

49.29%

17,896

6

To re-elect Isaac Kohlberg as a Director

63,450,417

99.66%

217,771

0.34%

63,668,188

49.29%

17,896

7

To re-elect Robert Lyne as a Director

63,451,455

99.66%

216,733

0.34%

63,668,188

49.29%

17,896

8

To elect Sir Michael Bunbury as a Director

60,231,844

94.60%

3,436,344

5.40%

63,668,188

49.29%

17,896

9

To appoint BDO LLP as auditors of the Company

63,659,891

99.98%

12,947

0.02%

63,672,838

49.29%

13,246

10

To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration

63,667,766

99.99%

4,772

0.01%

63,672,538

49.29%

13,546

11

To authorise the Directors to allot shares

63,632,590

99.94%

40,130

0.06%

63,672,720

49.29%

13,364

12

Authority to disapply statutory pre‐ emption rights

58,648,467

92.11%

5,021,253

7.89%

63,669,720

49.29%

16,364

13

Additional authority to disapply statutory pre‐ emption rights

58,653,953

92.12%

5,015,767

7.88%

63,669,720

49.29%

16,364

14

To authorise the Company to purchase its own shares

63,648,630

99.96%

22,560

0.04%

63,671,190

49.29%

14,894

15

Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice

63,666,745

99.99%

8,786

0.01%

63,675,531

49.29%

10,553

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2022, which is available on Arix investor relations website.

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

ISIN:GB00BD045071
Category Code:RAG
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:166768
EQS News ID:1370371
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

3456789101112
Date   Source Headline
31st Mar 20215:39 pmEQSTransaction in own shares
30th Mar 20215:09 pmEQSTransaction in own shares
30th Mar 20211:02 pmEQSArix leads $152 million Series B financing for Pyxis Oncology
30th Mar 20217:00 amEQSGita Dittmar appointed as Venture Partner
29th Mar 20215:14 pmEQSTransaction in own shares
29th Mar 20217:00 amEQSBoard update
26th Mar 20215:14 pmEQSTransaction in own shares
25th Mar 20214:58 pmEQSTransaction in own shares
24th Mar 20215:05 pmEQSTransaction in own shares
24th Mar 20217:00 amEQSStrategy Implementation Review
23rd Mar 20215:27 pmEQSTransaction in own shares
22nd Mar 20215:57 pmEQSTransaction in own shares
22nd Mar 202111:09 amEQSAura Biosciences announces oversubscribed $80 million financing
22nd Mar 20217:00 amEQSShare buyback programme of up to £25 million
19th Mar 20214:00 pmEQSHolding(s) in Company
15th Mar 20217:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): 32% IRR since inception in 2016
15th Mar 20217:00 amEQSShare buyback programme of up to £25 million
10th Mar 20217:01 amEQSResponse to Activist Shareholder Acacia
9th Mar 20217:01 amEQSArix founds new portfolio company Twelve Bio
9th Mar 20217:01 amEQSAnnual Results for the Twelve Months ended 31 December 2020
25th Feb 20217:00 amEQSBoard Changes
15th Feb 20219:00 amEQSHolding(s) in Company
11th Feb 20217:00 amEQSNotice of Results
10th Feb 20219:00 amEQSAutolus announces pricing of public offering
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20219:06 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amEQSInvestment team changes
12th Jan 20217:00 amEQSHarpoon announces closing of public offering
6th Jan 20212:00 pmEQSImara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
6th Jan 202110:00 amEQSAutolus provides business outlook for 2021 and 2022
31st Dec 20209:00 amRNSPrice Monitoring Extension
21st Dec 20207:00 amEQSDirector Share Purchase
18th Dec 20208:00 amEQSCompletion of sale of VelosBio
11th Dec 20207:00 amEQSAtox Bio announces FDA acceptance of New Drug Application
8th Dec 20203:45 pmEQSHarpoon reports clinical progress across all pipeline development programmes
7th Dec 20205:48 pmEQSAutolus presents additional data on AUTO3 at ASH
7th Dec 20207:15 amEQSHardman & Co Research: Arix Bioscience (ARIX): Artios attracts Merck KGaA in deal up to $7bn
7th Dec 20207:01 amEQSAutolus presents positive AUTO1 data at ASH
4th Dec 20207:01 amEQSHolding(s) in Company
4th Dec 20207:00 amEQSHolding(s) in Company
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20208:01 amEQSArtios and Merck KGaA announce global strategic collaboration
12th Nov 20207:00 amEQSArix to Present at the Jefferies Virtual London Healthcare Conference
6th Nov 202012:10 pmEQSHardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
5th Nov 20202:06 pmRNSSecond Price Monitoring Extn
5th Nov 20202:00 pmRNSPrice Monitoring Extension
5th Nov 202011:38 amEQSArix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.